Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

126.07USD
23 Jun 2017
Change (% chg)

-- (--)
Prev Close
$126.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
866,130
52-wk High
$145.29
52-wk Low
$96.18

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $28,309.84
Shares Outstanding(Mil.): 224.56
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 59.87 13.63 17.39
EPS (TTM): 2.11 -- --
ROI: 3.85 -6.95 -5.22
ROE: 5.64 -6.42 -4.48

BRIEF-Alexion receives positive CHMP opinion for Soliris in the EU

* Alexion receives positive CHMP opinion for Soliris (eculizumab) for the treatment of patients with refractory Generalized Myasthenia Gravis (GMG) in the European Union

23 Jun 2017

REFILE-Alexion names Biogen's Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31.

14 Jun 2017

BRIEF-Alexion Pharmaceuticals in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million

* Alexion Pharmaceuticals Inc - in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million

14 Jun 2017

BRIEF-Alexion Pharmaceuticals names Paul Clancy as CFO

* Alexion Pharmaceuticals Inc - Clancy will succeed Dave Anderson, who will continue to serve as CFO until july 31, 2017

14 Jun 2017

Alexion's shares plunge on latest top level exits

Alexion Pharmaceuticals Inc said on Tuesday its chief financial officer and research head would leave in the latest top level exits, sending the company's shares down 11 percent to a more-than-three-and-half year low.

23 May 2017

BRIEF-Alexion Pharmaceuticals says long-term data confirm benefits of Strensiq

* Alexion Pharmaceuticals - long-term data confirm benefits of treatment with strensiq in adolescents and adults with hypophosphatasia through 5 years Source text for Eikon: Further company coverage:

15 May 2017

UPDATE 2-Brazilian police search Alexion offices in fraud probe

SAO PAULO, May 8 Brazilian police searched the Sao Paulo offices of drugmaker Alexion Pharmaceuticals Inc on Monday as part of a probe into its relationship with a patient advocacy group accused of filing fraudulent lawsuits to spur drug purchases.

09 May 2017

BRIEF-Alexion Pharmaceuticals Q1 non-GAAP earnings per share $1.38

* Raises FY 2017 non-GAAP earnings per share view $5.10 to $5.30

27 Apr 2017

UPDATE 2-Alexion Pharma names former Baxalta chief Ludwig Hantson CEO

March 27 Alexion Pharmaceuticals Inc on Monday named former Baxalta CEO Ludwig Hantson to its top job, as the rare-disease drug maker seeks to regain investor confidence following the exit of top management.

27 Mar 2017

Alexion Pharma names former Baxalta head Ludwig Hantson CEO

March 27 Alexion Pharmaceuticals Inc said it named former Baxalta head Ludwig Hantson chief executive officer as the rare-disease drug maker looks to steady the ship following the exit of its top management.

27 Mar 2017

More From Around the Web

Competitors

Earnings vs. Estimates